Riskpilot← Back to searchSign inGet full accessOdeum Pharma AB
ABActiveOrg 5566023387Kungsvillan 1Manufacture of pharmaceutical preparations · NACE 2120Est. 20010 employees
Revenue 2025
SEK 174K
-27% vs 2024
EBITDA margin
-5.7%
-121% vs 2024
Equity ratio
78.7%
Financial strength
Net profit 2025
SEK 65K
-89% vs 2024
| Revenue | SEK 174K | -27% |
| EBITDA | SEK -10K | -121% |
| Net profit | SEK 65K | -89% |
| Total assets | SEK 14,7M | +2% |
| Equity | SEK 11,6M | +1% |
| Employees | 0 | — |
Legal name
Odeum Pharma AB
Org number
5566023387
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
25 januari 2001
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva marknadsföring av läkemedel och natur- läkemedel till sjukvården och allmänheten, ävensom att äga och förvalta fast och lös egendom, samt att idka därmed sammanhängande verksamhet.
Address
Kungsvillan 1
Phone
+46705682041
Email
jan-eric.ternstrom@odempharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 92 | 141 | 147 | 231 | 215 | 235 | 239 | 174 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −214 | −605 | −1 072 | −837 | −251 | −283 | −392 | −165 | 48 | −10 |
| Depreciation & amort. | −137 | −137 | −147 | −76 | −76 | −76 | −76 | −76 | −76 | −76 |
| EBIT | −351 | −742 | −1 219 | −913 | −327 | −359 | −468 | −241 | −28 | −86 |
| Net financials | −66 | 994 | 445 | 534 | 22 | 18 | — | 60 | 481 | 442 |
| Profit before tax | 1 966 | 2 051 | 2 037 | 795 | 10 | 11 | 13 | 51 | 736 | 84 |
| Tax | −461 | −264 | −394 | −0 | −7 | −8 | −11 | −18 | −163 | −19 |
| Net profit | 1 505 | 1 787 | 1 643 | 795 | 3 | 3 | 2 | 33 | 573 | 65 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 41 231 | 41 029 | 39 815 | 16 301 | 16 013 | 15 256 | 14 183 | 14 182 | 14 395 | 14 705 |
| Equity | 28 629 | 30 252 | 12 895 | 13 690 | 12 893 | 12 896 | 12 898 | 10 931 | 11 504 | 11 570 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 708 | 682 | 19 636 | 477 | 1 301 | 947 | 395 | 2 632 | 2 600 | 2 814 |
| Total debt | 708 | 682 | 19 636 | 477 | 1 301 | 947 | 395 | 2 632 | 2 600 | 2 814 |
EBITDA margin
-5.7%
This company
15.8%
Market median
-136% vs market
20162025
Equity ratio
78.7%
This company
38.2%
Market median
+106% vs market
20162025
Return on equity
0.6%
This company
18.4%
Market median
-97% vs market
20162025
Net profit margin
37.4%
This company
8.1%
Market median
+362% vs market
20162025
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20162025
Debt / equity
0.27×
This company
0.62×
Market median
+56% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-05-01 – 2020-04-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-05-01 – 2016-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LG | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Odeum Holding AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Odeum Holding AB
Odeum Pharma AB Board members of Odeum Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Gunnar Harald Engström | Audit | 0 companies |
| Jan Erik Ternström | Board of Directors | 0 companies |
| Johanna Isabel Ternström | Deputy Board Member | 0 companies |